Relmada Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
106.7M
on 2026-06-30, from 30.2M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-05-13. An automatic shelf: the form sets no dollar limit. None sold under it to 2026-10-05. S-3ASR ↗
$100.0M
Agreement of 2026-01-30. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗
Warrants
The 10-Q filed 2026-08-06 is not read yet.
Cash
18.9 quarters
$217.7M on 2026-06-30 ÷ $11.5M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-03-09 | Private placement incl. 4.21M pre-funded | 33,685,096 | $4.75 | $160.0M | 8-K ↗ |
| 2025-11-04 | Public offering incl. 5.32M pre-funded | 45,457,000 | $2.20 | $100.0M | 424B5 ↗ |